Traditional Therapy Profiles · Product pattern

Cystone-type
kidney support

Also called: stone tablet, urinary tonic, Himalaya Cystone, Uricare

Pattern families: Pasanabheda · Shilajit · Rubia cordifolia · Proprietary blend

One brand became the category.

New here? How to read these profiles

The important distinction

Cystone is one proprietary formulation. Patients often use the name the way they might say Kleenex: one brand standing in for an entire stone-support type. Evidence follows the branded product that was studied, not every tablet filed under "Cystone," and not classical urinary vatis such as Chandraprabha.

What it is

Cystone-type kidney support is an OTC urinary and stone-support tablet pattern anchored by proprietary multi-herb formulas, most famously Himalaya Cystone (marketed as Uricare in some regions). Labels usually stack pasanabheda, shilajit, rubia, and related litholytic herbs in ratios fixed by the manufacturer, not by a classical vati recipe.

One brand became the category. Its reputation grew because the name is what patients reach for in stone conversations. The name now covers a broader category than the product that generated the evidence.

Where you will encounter it

  • "Stone tablet" and "urinary tonic" shelves beside mainstream vitamins
  • Patients who ask whether "Cystone" is good, then reveal they are taking a different stone product
  • Resident and practitioner conversations that treat the brand as the whole urinary OTC category
  • Post-colic and post-ESWL recovery advice that overlaps with hydration and general tonic language

Further detail

Brand as category

Patients use one brand name for an entire product type.

Himalaya fixed pasanabheda, shilajit, and related litholytic herbs into one branded stone-support line decades before competitor urinary tablets filled the same shelf. That success made Cystone the word patients reach for when they mean kidney or urinary support in general, including products that are not Cystone at all. Brand recognition is not proof that every tablet filed under the name shares one evidence file. A proprietary stone-support blend belongs to a different tradition from a classical urinary vati such as Chandraprabha.

What human research has studied

Evidence attaches to the branded product that was studied, not to every tablet filed under the name.

A 2020 systematic review pooled five RCTs on Cystone for urolithiasis, reporting greater stone-size reduction and clearance rates versus placebo while noting high heterogeneity, low Jadad scores, and inconsistent results in crossover studies. An earlier manufacturer meta-analysis of fifty clinical studies adds real-world tolerability and clearance data on the branded line, though many included studies predate modern trial standards.

Those trials attach to Himalaya's proprietary formulation alone. They do not validate every competitor capsule filed under the name, or classical urinary vatis such as Chandraprabha filed in the same conversation.

What the evidence does not justify
  • Using "Cystone" as the name for any stone or urinary-support tablet, including competitors that are not that brand
  • Assuming every stone tablet replicates a Cystone trial arm
  • Equating proprietary litholytic blends with classical urinary vatis such as Chandraprabha
  • Replacing urology follow-up, imaging, or surgical planning on supplement marketing
  • Treating selective size-reduction signals in small trials as settled stone disease management
Questions worth asking

The useful first question is "Cystone, or a competitor stone tablet?"

  • Which brand and product: Cystone, Uricare, or a competitor "stone tablet"?
  • Is this for active passage, prevention after a prior stone, or general urinary wellness?
  • Classical urinary vati on the label, or a proprietary OTC blend?
  • Known stone size, location, composition, or obstructive symptoms in the picture?
Safety and interaction attention

Safety follows the product in hand, not the category name alone.

Published Cystone trials and the manufacturer meta-analysis report few intervention-related adverse events. That tolerability profile is not a substitute for urology oversight when stones are obstructing, infection is present, or surgery is already planned. Quality variability and concurrent conventional urinary medicines remain practical counseling topics.

Related entries

One brand name. Several different products behind the speech, including classical urinary vatis.

  1. Chandraprabha Vati Classical urinary vati Herbomineral rasaushadhi with its own trial file. Not interchangeable with proprietary Cystone-type OTC blends.
  2. Gokshuradi Guggulu Formulation Sugar and urine overlap in prescribing conversations. Classical guggulu vati, not stone-tablet brand shorthand.
  3. Himalaya Cystone Brand anchor for this product category The name patients and residents use for the whole category. Systematic review and manufacturer meta-analysis data attach to this product line, not every shelf competitor.

Commonly confused with

  • Chandraprabha Vati and other classical urinary vatis (different product class, different evidence file)
  • Gokshuradi Guggulu when sugar and urine conversations collapse into one tablet name
  • Competitor "stone tablet" products marketed beside Cystone (similar category language, different unpublished blend proof)
  • Liv.52-type liver support (same product-pattern logic, different organ category)
  • Urology surgical planning and imaging follow-up (different regulatory and monitoring standards)
Sources
  1. Azarfar A, Rafiee Z, Ravanshad Y, Moghadam NS, Bakhtiari E. Effect of Herbal Formulation "Cystone®" on Urolithiasis. Jundishapur J Nat Pharm Prod. 2020. doi:10.5812/jjnpp.69246
  2. Karamakar D, Patki PS. Evaluation of efficacy and safety of a herbal formulation Cystone in the management of urolithiasis: Meta-analysis of 50 clinical studies. Internet J Altern Med. 2010. doi:10.5580/15ea

Evidence blocks last reviewed: July 2026.

← Back to Traditional Therapy Profiles